Tofersen was approved in 2023 for the treatment of amyotrophic lateral sclerosis, specifically in patients diagnosed with mutations in the superoxide dismutase 1 (SOD1) gene [151]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.